Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients - Full Text View

Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients

This study has been completed.

Sponsored by:	University of Southern California
Information provided by:	NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:	NCT00002052

Purpose

To compare the effectiveness of standard treatment with parenteral ampicillin and oral amoxicillin compared to initial daily therapy with ceftriaxone followed by 3 times weekly suppressive treatment for salmonella infections in AIDS patients.

Condition	Intervention
HIV Infections Salmonella Infections	Drug: Ceftriaxone sodium Drug: Ampicillin sodium Drug: Amoxicillin trihydrate

MedlinePlus related topics:

AIDS Salmonella Infections

ChemIDplus related topics:

Ceftriaxone Ceftriaxone Sodium Amoxicillin Amoxicillin sodium Amoxicillin trihydrate Ampicillin Ampicillin sodium Ampicillin trihydrate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Dose Comparison

Official Title:	Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

Type I hypersensitivity to beta-lactam antibiotics.
Not expected to survive 12 weeks.
In a coma or with other central nervous system (CNS) impairment.

Patients with the following are excluded:

Type I hypersensitivity to beta-lactam antibiotics.
Not expected to survive 12 weeks.
In a coma or with other central nervous system (CNS) impairment.

Prior Medication:

Excluded within 48 hours of study entry:

Treatment with an antibiotic active in vitro against Salmonella.

HIV infection, AIDS, or AIDS related complex (ARC).

Salmonella bacteremia or positive stool culture in patient with 3 or more stools per day.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002052

Locations


United States, California
	Los Angeles County - USC Med Ctr
	Los Angeles, California, United States, 90033

Sponsors and Collaborators

University of Southern California

More Information

Study ID Numbers:	019A
First Received:	November 2, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00002052
Health Authority:	United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:

Salmonella Infections

AIDS-Related Opportunistic Infections

Acquired Immunodeficiency Syndrome

Amoxicillin

Ceftriaxone

Study placed in the following topic categories:

Bacterial Infections

Opportunistic Infections

Amoxicillin

Sexually Transmitted Diseases, Viral

Salmonella Infections

Enterobacteriaceae Infections

Acquired Immunodeficiency Syndrome

Ampicillin

Ceftriaxone

Immunologic Deficiency Syndromes

Gram-Negative Bacterial Infections

Virus Diseases

HIV Infections

AIDS-Related Opportunistic Infections

Sexually Transmitted Diseases

Retroviridae Infections

Additional relevant MeSH terms:

Anti-Infective Agents

Anti-Bacterial Agents

Communicable Diseases

RNA Virus Infections

Slow Virus Diseases

Immune System Diseases

Therapeutic Uses

Lentivirus Infections

Infection

Pharmacologic Actions

ClinicalTrials.gov processed this record on October 10, 2008